Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro

Breast tumour kinase (Brk/PTK6) is overexpressed in up to 86% of breast cancers and is associated with poorer patient outcomes. It is considered a potential therapeutic target in breast cancer, even though the full spectrum of its kinase activity is not known. This study investigated the role of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmi, Rajpal S., Box, Gary M., Wazir, Umar, Hussain, Haroon A., Davies, Julie A., Court, William J., Eccles, Suzanne A., Jiang, Wen G., Mokbel, Kefah, Harvey, Amanda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950834/
https://www.ncbi.nlm.nih.gov/pubmed/35327957
http://dx.doi.org/10.3390/genes13030402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950834/
https://www.ncbi.nlm.nih.gov/pubmed/35327957
http://dx.doi.org/10.3390/genes13030402

Ejemplares similares